Background Prolonged dual antiplatelet therapy (DAPT) in patients undergoing
percutaneous coronary intervention (PCI) has been associated with an increased risk of …

Aims Current guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and a
P2Y12 inhibitor for 6–12 months after percutaneous coronary intervention (PCI). A shorter …

Dual antiplatelet therapy (DAPT) and subsequent P2Y12 inhibitor monotherapy, particularly
ticagrelor, is an emerging treatment strategy in patients undergoing percutaneous coronary …

(1) Shorter-duration dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy
has been shown to significantly reduce bleeding events while preserving anti-ischemic …

Background: We aimed to systematically evaluate the efficacy and safety ticagrelor
monotherapy following percutaneous coronary intervention. Methods: Online databases …

Objectives The aim of this study was to compare ticagrelor monotherapy with dual-
antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting …

Importance Among patients undergoing percutaneous coronary intervention (PCI), it
remains unclear whether the treatment efficacy of P2Y 12 inhibitor monotherapy after a short …

Aims To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy
following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month …

Patients undergoing staged percutaneous coronary intervention (SPCI) are exposed to
extended duration of antiplatelet therapy, and a novel aspirin-free antiplatelet regimen after …

Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …